ES485715A1 - Procedimiento mejorado para la preparacion de proteinas de membranas - Google Patents

Procedimiento mejorado para la preparacion de proteinas de membranas

Info

Publication number
ES485715A1
ES485715A1 ES485715A ES485715A ES485715A1 ES 485715 A1 ES485715 A1 ES 485715A1 ES 485715 A ES485715 A ES 485715A ES 485715 A ES485715 A ES 485715A ES 485715 A1 ES485715 A1 ES 485715A1
Authority
ES
Spain
Prior art keywords
membrane proteins
preparation
improved procedure
optionally
detergent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
ES485715A
Other languages
English (en)
Spanish (es)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Siemens Healthcare Diagnostics GmbH Germany
Original Assignee
Behringwerke AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Behringwerke AG filed Critical Behringwerke AG
Publication of ES485715A1 publication Critical patent/ES485715A1/es
Expired legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • A61K39/095Neisseria

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ES485715A 1978-11-11 1979-11-06 Procedimiento mejorado para la preparacion de proteinas de membranas Expired ES485715A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19782848965 DE2848965A1 (de) 1978-11-11 1978-11-11 Verfahren zur herstellung von membranproteinen aus neisseria meningitidis und diese enthaltende vaccine

Publications (1)

Publication Number Publication Date
ES485715A1 true ES485715A1 (es) 1980-05-16

Family

ID=6054405

Family Applications (1)

Application Number Title Priority Date Filing Date
ES485715A Expired ES485715A1 (es) 1978-11-11 1979-11-06 Procedimiento mejorado para la preparacion de proteinas de membranas

Country Status (9)

Country Link
EP (1) EP0011243B1 (esLanguage)
JP (1) JPS5566519A (esLanguage)
AT (1) ATE857T1 (esLanguage)
AU (1) AU533386B2 (esLanguage)
CA (1) CA1142083A (esLanguage)
DE (2) DE2848965A1 (esLanguage)
DK (1) DK154841C (esLanguage)
ES (1) ES485715A1 (esLanguage)
IL (1) IL58673A (esLanguage)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4317811A (en) 1980-09-11 1982-03-02 Merck & Co., Inc. Herpes simplex type 1 subunit vaccine
CA1221626A (en) * 1982-12-02 1987-05-12 Milan Blake Iga binding protein
US7118757B1 (en) 1988-12-19 2006-10-10 Wyeth Holdings Corporation Meningococcal class 1 outer-membrane protein vaccine
DE69934225T2 (de) 1998-05-29 2007-09-27 Novartis Vaccines and Diagnostics, Inc., Emeryville Kombinierte meningitis b/c impfstoffe
ES2563650T3 (es) 1999-05-19 2016-03-15 Glaxosmithkline Biologicals Sa Composiciones de combinaciones de Neisseria
GB9918319D0 (en) 1999-08-03 1999-10-06 Smithkline Beecham Biolog Vaccine composition
GB9928196D0 (en) 1999-11-29 2000-01-26 Chiron Spa Combinations of B, C and other antigens
PT1248647E (pt) 2000-01-17 2010-11-18 Novartis Vaccines & Diagnostics Srl Vacina de vesícula da membrana externa (omv) compreendendo proteínas de membrana externa de n. meningitidis do serogrupo b
GB0103171D0 (en) 2001-02-08 2001-03-28 Smithkline Beecham Biolog Vaccine composition
EP1524992B1 (en) 2002-08-02 2015-03-04 GlaxoSmithKline Biologicals s.a. Vaccine compositions comprising l2 and/or l3 immunotype lipooligosaccharides from lgtb- neisseria menigitidis
GB0220194D0 (en) 2002-08-30 2002-10-09 Chiron Spa Improved vesicles
CU23313A1 (es) 2002-11-27 2008-09-25 Inst Finlay Ct De Investigacia Mã0/00todo de obtenciã"n de estructuras cocleares. composiciones vacunales y adyuvantes basados en estructuras cocleares y sus intermediarios
GB0316560D0 (en) 2003-07-15 2003-08-20 Chiron Srl Vesicle filtration
CA2550927A1 (en) * 2003-12-23 2005-07-14 Glaxosmithkline Biologicals S.A. A gram negative bacterium with reduced lps level in the outer membrane and use thereof for treating gram negative bacterial infection
GB0419627D0 (en) 2004-09-03 2004-10-06 Chiron Srl Immunogenic bacterial vesicles with outer membrane proteins
GB0424092D0 (en) 2004-10-29 2004-12-01 Chiron Srl Immunogenic bacterial vesicles with outer membrane proteins
US20090123499A1 (en) 2006-06-12 2009-05-14 Nathalie Devos Vaccine
BR122016015627A2 (pt) 2007-10-19 2018-10-30 Novartis Ag kit, composição antigênica liofilizada e método para preparação de uma composição imunogênica
CA2716212A1 (en) 2008-02-21 2009-08-27 Novartis Ag Meningococcal fhbp polypeptides
GB0822634D0 (en) 2008-12-11 2009-01-21 Novartis Ag Meningitis vaccines
WO2010070453A2 (en) 2008-12-17 2010-06-24 Novartis Ag Meningococcal vaccines including hemoglobin receptor
US9517263B2 (en) 2009-06-10 2016-12-13 Glaxosmithkline Biologicals Sa Benzonaphthyridine-containing vaccines
EP3017828A1 (en) 2009-08-27 2016-05-11 GlaxoSmithKline Biologicals SA Hybrid polypeptides including meningococcal fhbp sequences
EP2470205A1 (en) 2009-08-27 2012-07-04 Novartis AG Adjuvant comprising aluminium, oligonucleotide and polycation
TWI445708B (zh) 2009-09-02 2014-07-21 Irm Llc 作為tlr活性調節劑之化合物及組合物
GB0917003D0 (en) 2009-09-28 2009-11-11 Novartis Vaccines Inst For Global Health Srl Purification of bacterial vesicles
EP2483390A2 (en) 2009-09-30 2012-08-08 Novartis AG Expression of meningococcal fhbp polypeptides
CN102917730A (zh) 2009-10-27 2013-02-06 诺华有限公司 修饰的脑膜炎球菌fHBP多肽
WO2011057148A1 (en) 2009-11-05 2011-05-12 Irm Llc Compounds and compositions as tlr-7 activity modulators
CN102762206A (zh) 2009-12-15 2012-10-31 诺华有限公司 免疫增强化合物的均匀悬液及其用途
US20130004530A1 (en) 2010-03-10 2013-01-03 Jan Poolman Vaccine composition
WO2012020326A1 (en) 2010-03-18 2012-02-16 Novartis Ag Adjuvanted vaccines for serogroup b meningococcus
EA023725B1 (ru) 2010-03-23 2016-07-29 Новартис Аг Соединения (липопептиды на основе цистеина) и композиции в качестве агонистов tlr2, применяемые для лечения инфекционных, воспалительных, респираторных и других заболеваний
GB201015132D0 (en) 2010-09-10 2010-10-27 Univ Bristol Vaccine composition
AU2011300418B2 (en) 2010-09-10 2016-05-12 Glaxosmithkline Biologicals Sa Meningococcus overexpressing NadA and/or NHBA and outer membrane vesicles derived therefrom
WO2012153302A1 (en) 2011-05-12 2012-11-15 Novartis Ag Antipyretics to enhance tolerability of vesicle-based vaccines
ES2654613T3 (es) 2012-02-02 2018-02-14 Glaxosmithkline Biologicals Sa Promotores para una expresión aumentada de proteínas en meningococos
JP2015517089A (ja) 2012-03-08 2015-06-18 ノバルティス アーゲー タンパク質ベースの髄膜炎菌ワクチンのためのインビトロ有効性アッセイ
NZ630133A (en) 2012-06-14 2016-10-28 Novartis Ag Vaccines for serogroup x meningococcus
CA2882619A1 (en) 2012-09-06 2014-03-13 Novartis Ag Combination vaccines with serogroup b meningococcus and d/t/p
JP6283674B2 (ja) 2012-09-18 2018-02-21 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 外膜小胞
RS61246B1 (sr) 2014-02-28 2021-01-29 Glaxosmithkline Biologicals Sa Modifikovani meningokokni fhbp polipeptidi
US12161707B2 (en) 2016-09-02 2024-12-10 Glaxosmithkline Biologicals Sa Vaccines for Neisseria gonorrhoeae
AU2018330322A1 (en) 2017-09-08 2020-03-19 Evelo Biosciences, Inc. Bacterial extracellular vesicles
EP3607967A1 (en) 2018-08-09 2020-02-12 GlaxoSmithKline Biologicals S.A. Modified meningococcal fhbp polypeptides
CA3117867A1 (en) 2018-11-06 2020-05-14 Glaxosmithkline Biologicals Sa Immunogenic compositions
EP3799884A1 (en) 2019-10-01 2021-04-07 GlaxoSmithKline Biologicals S.A. Immunogenic compositions
GB202115072D0 (en) 2021-10-21 2021-12-08 Glaxosmithkline Biologicals Sa Assay
GB202115077D0 (en) 2021-10-21 2021-12-08 Glaxosmithkline Biologicals Sa Assay
GB202211033D0 (en) 2022-07-28 2022-09-14 Glaxosmithkline Biologicals Sa Purification process

Also Published As

Publication number Publication date
IL58673A (en) 1983-02-23
IL58673A0 (en) 1980-02-29
EP0011243A1 (de) 1980-05-28
DK475779A (da) 1980-05-12
CA1142083A (en) 1983-03-01
DK154841B (da) 1988-12-27
JPS5566519A (en) 1980-05-20
DE2848965A1 (de) 1980-05-22
DK154841C (da) 1989-06-05
AU5268279A (en) 1980-05-15
ATE857T1 (de) 1982-04-15
AU533386B2 (en) 1983-11-24
EP0011243B1 (de) 1982-04-14
DE2962526D1 (en) 1982-05-27
JPS6350332B2 (esLanguage) 1988-10-07

Similar Documents

Publication Publication Date Title
ES485715A1 (es) Procedimiento mejorado para la preparacion de proteinas de membranas
DE69423383D1 (de) Herstellung und Verwendungen von LOS-verminderten Aussenmembran-Proteinen von Gram-negativen Kokken
ATE59402T1 (de) Verfahren zur abtrennung von cholesterin aus fettsubstanzen tierischen ursprungs und cholesterinarme fettsubstanzen.
ES8104412A1 (es) Procedimiento para la preparacion de un hidrolizado de pro- teinas purificado.
ES486893A1 (es) Procedimiento para la preparacion de material sustitutivo dehuesos
ATE92720T1 (de) Verfahren zur modifizierung von molke.
Blank The chemical composition of the cell walls of dermatophytes
DE3686961D1 (de) Polydisperse native pseudomonas-flagella(h)-antigene (fag) und verfahren zu ihrer gewinnung.
ATE201882T1 (de) Formulierung von energie
ATE72756T1 (de) Verfahren zur herstellung eines biologischen stoffes.
DE3854096D1 (de) Verfahren zur Isolierung von Basalmembranproteinen aus menschlichen und tierischen Geweben.
ES8104789A1 (es) Procedimiento para la separacion de leucina, isoleucina y valina
DE3265664D1 (en) Process for the production of a biochemical vaccine against salmonella fevers
US2433879A (en) Manufacture of amino acid preparations intended for intravenous supply of nutrients
FR2429765A1 (fr) Procede et agent d'adsorption pour isoler des enzymes et pour les preparer a l'etat pur
ATE116989T1 (de) Verfahren zur reinigung von hemin, neues heminderivat und verfahren zur herstellung.
GB2021120A (en) Process for obtaining food proteins of vegetable origin with elimination of the toxic and non proteinic substances
DE3565535D1 (en) Process for the preparation of optically active 1,4-dihydropyridines
ATE101393T1 (de) Phenanthridinderivate, verfahren zu ihrer herstellung und mittel zur ausfuehrung des verfahrens.
ES2059401T3 (es) Procedimiento microbiologico para la obtencion de una proteina mediante cultivo de una cepa bacteriana mutante.
Silverman et al. Production of protective antigens by Pasteurella pestis in a synthetic medium
ES450053A1 (es) Un procedimiento para elaborar un producto de proteina tex- turizada.
SU1515606A1 (ru) Способ очистки и выделения нитропруссида натрия
JPS57201600A (en) Treatment of organic sludge
SU1524226A1 (ru) Способ получения аллергена из пчелиного яда

Legal Events

Date Code Title Description
PC1A Transfer granted
FD1A Patent lapsed

Effective date: 20000201